\name{dat.linde2005}
\docType{data}
\alias{dat.linde2005}
\title{Studies on the Effectiveness of St. John's Wort for Treating Depression}
\description{Results from 26 studies on the effectiveness of Hypericum perforatum extracts (St. John's wort) for treating depression.}
\usage{dat.linde2005}
\format{The data frame contains the following columns:
\tabular{lll}{
\bold{id}       \tab \code{numeric}   \tab study number \cr
\bold{study}    \tab \code{character} \tab study author(s) \cr
\bold{year}     \tab \code{numeric}   \tab publication year \cr
\bold{country}  \tab \code{character} \tab study location \cr
\bold{ni}       \tab \code{numeric}   \tab total sample size \cr
\bold{major}    \tab \code{numeric}   \tab sample restricted to patients who met criteria for major depression \cr
\bold{baseline} \tab \code{numeric}   \tab HRSD baseline score \cr
\bold{version}  \tab \code{numeric}   \tab HRSD version (17 or 21 items) \cr
\bold{duration} \tab \code{numeric}   \tab study duration (in weeks) \cr
\bold{prep}     \tab \code{character} \tab Hypericum extract preparation \cr
\bold{dosage}   \tab \code{numeric}   \tab doage (in mg) \cr
\bold{response} \tab \code{numeric}   \tab definition of response (1 = HRSD score reduction of at least 50\% or HRSDscore after therapy <10; 2 = HRSDreduction of at least 50\%; 3 = based on HRSD scale but exact definition not reported; 4 = global patient assessment of efficacy; 5 = at least 'much improved' on the Clinical Global Impression sub-scale global improvement) \cr
\bold{ai}       \tab \code{numeric}   \tab number of responses in treatment group \cr
\bold{n1i}      \tab \code{numeric}   \tab number of patients in treatment group \cr
\bold{ci}       \tab \code{numeric}   \tab number of responses in placebo group \cr
\bold{n2i}      \tab \code{numeric}   \tab number of patients in placebo group \cr
\bold{group}    \tab \code{numeric}   \tab stratification variable used by the authors (1 = smaller trials restricted to major depression; 2 = larger trials restricted to major depression; 3 = smaller trials not restricted to major depression; 4 = larger trials not restricted to major depression)
}
}
\details{
   The dataset includes the results from 26 double-blind placebo-controlled trials on the effectiveness of Hypericum perforatum extracts (St. John's wort) for treating depression (note that 2 studies did not provide sufficient response information).

   Data were extracted from Table 1 and Figure 3. For study duration, the assessment week (instead of the total study duration) was coded for Philipp et al. (1999) and Montgomery et al. (2000). For dosage, the midpoint was coded when a range of values was given.
}
\source{
   Linde, K., Berner, M., Egger, M., & Mulrow, C. (2005). St John's wort for depression: Meta-analysis of randomised controlled trials. \emph{British Journal of Psychiatry}, \bold{186}, 99--107.
}
\references{
   Viechtbauer, W. (2007). Accounting for heterogeneity via random-effects models and moderator analyses in meta-analysis. \emph{Zeitschrift fÃ¼r Psychologie / Journal of Psychology}, \bold{215}, 104--121.
}
\examples{
### load data
dat <- get(data(dat.linde2005))

### remove studies with no response information and study with no responses in either group
dat <- dat[-c(5,6,26),]

### calculate log relative risks and corresponding sampling variances
dat <- escalc(measure="RR", ai=ai, ci=ci, n1i=n1i, n2i=n2i, data=dat)

### meta-analysis of the log relative risks using a random-effects model
res <- rma(yi, vi, data=dat, method="DL")
res

### mixed-effects meta-regression model with stratification variable
res <- rma(yi, vi, mods = ~ factor(group) - 1, data=dat, method="DL")
res

### predicted average relative risk for each level of the stratification variable
predict(res, newmods=diag(4), transf=exp, digits=2)
}
\keyword{datasets}
